drugset / Trial / NCT05742594

A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants

NCT05742594

Phase 1 Completed 64 enrolled Janssen Research & Development, LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The purpose of this study is to assess the bioequivalence of four different lazertinib oral tablet formulations in healthy adult participants under fasted condition.

Timeline

Start
2023-01-03
Primary completion
2023-03-31
Completion
2023-04-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Lazertinib Small molecule Oral

Indications

No indication recorded.